Abstract | BACKGROUND:
Anemia in patients with solid tumors is a common problem that is associated with impaired exercise capacity, increased fatigue, and lower quality of life (QoL). Erythropoiesis-stimulating agents (ESAs) have been shown to improve these outcomes; however, it is unknown if additional benefits can be achieved with aerobic exercise training. METHODS: We conducted a single-center, prospective, randomized, controlled trial in 55 mild-to-moderately anemic patients with solid tumors. Patients were randomized to either darbepoetin alfa alone (DAL, n = 29) or darbepoetin alfa plus aerobic exercise training (DEX; n = 26). The DEX group performed aerobic exercise training three times per week at 60%-100% of baseline exercise capacity for 12 weeks. The primary endpoint was QoL assessed by the Functional Assessment of Cancer Therapy- Anemia scale. Secondary endpoints were fatigue, cardiorespiratory fitness (VO(2peak)), hemoglobin (Hb) response, and darbepoetin alfa dosing. RESULTS: Intention-to-treat analyses indicated significant improvements in QoL and fatigue in both groups over time but there were no between-group differences. The DEX group had a significantly greater VO(2peak) than the DAL group (mean group difference, +3.0 ml/kg per minute; 95% confidence interval, 1.2-4.7; p = .001) and there were borderline significant differences in favor of the DEX group for Hb response and darbepoetin alfa dosing. CONCLUSIONS: Aerobic exercise training did not improve QoL or fatigue beyond the established benefits of DAL but it did result in favorable improvements in exercise capacity and a more rapid Hb response with lower dosing requirements. Our results may be useful to clinicians despite the more recent restrictions on the indications for ESAs.
|
Authors | Kerry S Courneya, Lee W Jones, Carolyn J Peddle, Christopher M Sellar, Tony Reiman, Anil A Joy, Neil Chua, Linda Tkachuk, John R Mackey |
Journal | The oncologist
(Oncologist)
Vol. 13
Issue 9
Pg. 1012-20
(Sep 2008)
ISSN: 1549-490X [Electronic] England |
PMID | 18779540
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Erythropoietin
- Darbepoetin alfa
|
Topics |
- Adult
- Aged
- Anemia
(blood, drug therapy, physiopathology, therapy)
- Darbepoetin alfa
- Double-Blind Method
- Erythropoietin
(adverse effects, analogs & derivatives, therapeutic use)
- Exercise
- Exercise Therapy
(methods)
- Female
- Humans
- Male
- Middle Aged
- Neoplasms
(blood, complications)
- Quality of Life
- Surveys and Questionnaires
- Treatment Outcome
|